Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Genprex, Inc.GNPX · Entity 8441 | Director | December 30, 2019 | March 21, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Genprex, Inc.
Report date December 30, 2019 · Filed March 21, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2029-12-30 | Direct | 68,376 |
Reported balance
After 2019-12-30 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2019-12-30 · Grant · Acquired 68,376 · Balance 68,376 F1: Equal to the fair market value of a share of common stock on June 10, 2019, the date on which the option grant was to be made under the Genprex, Inc. Outside Director Compensation Policy. F2: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 10, 2019 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. F3: This Form 4 amendment is being filed to reflect that on March 18, 2020, the Option was amended to provide that one hundred percent (100%) of the Shares subject to the Option became exercisable on March 18, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Equal to the fair market value of a share of common stock on June 10, 2019, the date on which the option grant was to be made under the Genprex, Inc. Outside Director Compensation Policy.
F2: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 10, 2019 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date.
F3: This Form 4 amendment is being filed to reflect that on March 18, 2020, the Option was amended to provide that one hundred percent (100%) of the Shares subject to the Option became exercisable on March 18, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2019 Filed Jan 2, 2020 17:45 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 78,125 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001437749-20-000028 · rdgdoc.xml · derivative · entry 2 Friedman David E. · CIK 0001735757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,125 Underlying: Common Stock · 78,125 shares Expires 2029-12-30 F3 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the date of grant of the Option. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 17:45 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 68,376 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001437749-20-000028 · rdgdoc.xml · derivative · entry 1 Friedman David E. · CIK 0001735757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,376 Underlying: Common Stock · 68,376 shares Expires 2029-12-30 F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 10, 2019, the date on which the option grant was to be made under the Genprex, Inc. Outside Director Compensation Policy. F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 10, 2019 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. Read SEC document |
| December 30, 2019 Filed Mar 21, 2020 00:28 UTC Amendment | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 68,376 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001437749-20-005803 · rdgdoc.xml · derivative · entry 1 Friedman David E. · CIK 0001735757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,376 Underlying: Common Stock · 68,376 shares Expires 2029-12-30 F1 · derivative.exercise_price: Equal to the fair market value of a share of common stock on June 10, 2019, the date on which the option grant was to be made under the Genprex, Inc. Outside Director Compensation Policy. F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of June 10, 2019 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, provided that the Optionee continues to serve as a Service Provider (as defined in the Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date. F3 · derivative.exercise_date: This Form 4 amendment is being filed to reflect that on March 18, 2020, the Option was amended to provide that one hundred percent (100%) of the Shares subject to the Option became exercisable on March 18, 2020. Read SEC document |
| November 02, 2018 Filed Feb 5, 2019 16:07 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 101,156 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-19-007171 · doc4.xml · derivative · entry 2 Friedman David E. · CIK 0001735757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,156 Underlying: Common Stock · 101,156 shares Expires 2028-11-02 F2 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the earlier of (a) the one (1) year anniversary of November 2, 2018 and (b) the day prior to the Company's next annual meeting of the Company's stockholders occurring after the grant date, in each case, provided that the Optionee continues to serve as a Service Provider through the applicable vesting date. Read SEC document |
| November 02, 2018 Filed Feb 5, 2019 16:07 UTC | Genprex, Inc. GNPX · Entity 8441 | GrantStock Option (Right to Buy) · Derivative | 101,156 | $0.00 Strike: $2.15 | $0.00 |
DisclosureSEC source: 0001209191-19-007171 · doc4.xml · derivative · entry 1 Friedman David E. · CIK 0001735757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,156 Underlying: Common Stock · 101,156 shares Expires 2028-11-02 F1 · derivative.exercise_date: One hundred percent (100%) of the Shares subject to the Option shall vest upon the date of grant of the Option. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.